CeriBell, Inc. to announce 2025 financial results on February 24, 2026, with a conference call for investors.
Quiver AI Summary
CeriBell, Inc. announced it will release its financial results for the fourth quarter and full year of 2025 on February 24, 2026, after market close. A conference call for discussion of these results will take place at 1:30 p.m. PT / 4:30 p.m. ET on the same day, with details provided for both domestic and international callers. The company, which focuses on improving diagnosis and management of neurological conditions, has developed the Ceribell System, an innovative electroencephalography platform designed for acute-care settings. This system, which is FDA-cleared for detecting seizures and delirium in hospitals, leverages portable hardware and AI algorithms for rapid diagnosis and monitoring. CeriBell is based in Sunnyvale, California.
Potential Positives
- Ceribell will release financial results for Q4 and full year 2025, providing transparency and accountability to investors.
- The Ceribell System is FDA-cleared for use in detecting seizures and delirium, highlighting the company's innovative medical technology and regulatory compliance.
- The upcoming conference call offers investors an opportunity to engage directly with management and gain insights into the company's performance and future plans.
Potential Negatives
- e
FAQ
When will CeriBell announce its financial results for 2025?
CeriBell will release its financial results on February 24, 2026, after the market closes.
What time is the CeriBell conference call scheduled?
The conference call will begin at 1:30 p.m. PT / 4:30 p.m. ET on February 24, 2026.
How can investors join the CeriBell conference call?
Investors can join by dialing (800) 715-9871 for domestic calls or (646) 307-1963 internationally, and using access code 9394689.
Where can I find the webcast of the CeriBell financial results?
A live and archived webcast will be available in the "Investor Relations" section of the CeriBell website.
What is the focus of CeriBell, Inc.?
CeriBell focuses on transforming the diagnosis and management of serious neurological conditions through innovative medical technology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CBLL Insider Trading Activity
$CBLL insiders have traded $CBLL stock on the open market 40 times in the past 6 months. Of those trades, 0 have been purchases and 40 have been sales.
Here’s a breakdown of recent trading of $CBLL stock by insiders over the last 6 months:
- XINGJUAN CHAO (President and CEO) has made 0 purchases and 9 sales selling 218,000 shares for an estimated $4,108,037.
- JOSEF PARVIZI has made 0 purchases and 3 sales selling 75,000 shares for an estimated $1,617,250.
- RAYMOND WOO (Chief Technology Officer) has made 0 purchases and 10 sales selling 66,672 shares for an estimated $1,010,578.
- SCOTT BLUMBERG (Chief Financial Officer) has made 0 purchases and 3 sales selling 36,000 shares for an estimated $756,000.
- WILLIAM W BURKE has made 0 purchases and 2 sales selling 32,728 shares for an estimated $720,670.
- DAVID FOEHR (Senior VP, Finance and PAO) has made 0 purchases and 8 sales selling 17,243 shares for an estimated $335,436.
- REBECCA B ROBERTSON has made 0 purchases and 4 sales selling 9,154 shares for an estimated $177,905.
- JOSEPH MICHAEL TAYLOR sold 7,032 shares for an estimated $82,696
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CBLL Hedge Fund Activity
We have seen 63 institutional investors add shares of $CBLL stock to their portfolio, and 45 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF NEW YORK MELLON CORP added 1,162,200 shares (+1945.9%) to their portfolio in Q4 2025, for an estimated $25,487,046
- NOVO HOLDINGS A/S removed 900,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $10,341,000
- ROYCE & ASSOCIATES LP added 533,300 shares (+inf%) to their portfolio in Q4 2025, for an estimated $11,695,269
- CENTERBOOK PARTNERS LP added 389,584 shares (+448.0%) to their portfolio in Q3 2025, for an estimated $4,476,320
- FMR LLC removed 357,399 shares (-7.4%) from their portfolio in Q3 2025, for an estimated $4,106,514
- GOLDMAN SACHS GROUP INC added 314,324 shares (+2967.6%) to their portfolio in Q4 2025, for an estimated $6,893,125
- SOLEUS CAPITAL MANAGEMENT, L.P. added 310,000 shares (+620.0%) to their portfolio in Q3 2025, for an estimated $3,561,900
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CBLL Analyst Ratings
Wall Street analysts have issued reports on $CBLL in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 01/28/2026
- JP Morgan issued a "Overweight" rating on 11/05/2025
- TD Cowen issued a "Buy" rating on 11/05/2025
- Raymond James issued a "Strong Buy" rating on 10/21/2025
To track analyst ratings and price targets for $CBLL, check out Quiver Quantitative's $CBLL forecast page.
$CBLL Price Targets
Multiple analysts have issued price targets for $CBLL recently. We have seen 5 analysts offer price targets for $CBLL in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- Marie Thibault from BTIG set a target price of $30.0 on 01/28/2026
- William Plovanic from Canaccord Genuity set a target price of $30.0 on 12/17/2025
- Robbie Marcus from JP Morgan set a target price of $17.0 on 11/05/2025
- Joshua Jennings from TD Cowen set a target price of $20.0 on 11/05/2025
- Jayson Bedford from Raymond James set a target price of $19.0 on 10/21/2025
Full Release
SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Tuesday, February 24, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on February 24, 2026.
Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 9394689. A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/ .
Ab
out CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit
www.ceribell.com
or follow the company on
LinkedIn
.
Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
[email protected]
Media Contact
Brian Price
[email protected]
